Castle Biosciences (CSTL) CCO sells 1,301 shares at $38.39
Rhea-AI Filing Summary
Castle Biosciences Inc Chief Commercial Officer Juvenal Tobin W reported selling 1,301 shares of common stock on 2025-11-24 at $38.39 per share in an open-market or private transaction. Following the sale, he directly holds 77,694 shares. The trade was executed under a Rule 10b5-1 plan adopted on September 11, 2024.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 1,301 shares
Net Sell
1 txn
Insider
Juvenal Tobin W
Role
Chief Commercial Officer
Sold
1,301 shs ($50K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 1,301 | $38.39 | $50K |
Holdings After Transaction:
Common Stock — 77,694 shares (Direct)
Footnotes (1)
- F1. This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024.
Key Figures
Shares sold: 1,301 shares
Sale price per share: $38.39
Shares held after transaction: 77,694 shares
+1 more
4 metrics
Shares sold
1,301 shares
Common stock sale on 2025-11-24 by Chief Commercial Officer
Sale price per share
$38.39
Per-share price for the 1,301 Castle Biosciences shares sold
Shares held after transaction
77,694 shares
Direct holdings of Juvenal Tobin W following the reported sale
Net shares sold in filing
1,301 shares
Net-sell direction per transaction summary for this Form 4
Key Terms
Rule 10b5-1 plan, open market or private transaction, Chief Commercial Officer
3 terms
Rule 10b5-1 plan regulatory
"This transaction was made pursuant to a Rule 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
open market or private transaction financial
"Transaction code describes a sale in open market or private transaction"
Chief Commercial Officer other
"Reporting person serves as Chief Commercial Officer of the issuer"
A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did CSTL report for Juvenal Tobin W?
Castle Biosciences Inc (CSTL) reported that Chief Commercial Officer Juvenal Tobin W sold 1,301 shares of common stock. The sale occurred on 2025-11-24 in an open-market or private transaction at $38.39 per share under a Rule 10b5-1 plan.
Was the CSTL insider sale made under a Rule 10b5-1 plan?
Yes. The sale of 1,301 Castle Biosciences (CSTL) shares was made pursuant to a Rule 10b5-1 plan. The plan was adopted by the reporting person on September 11, 2024, indicating the trades were pre-arranged rather than discretionary.
Who is the insider involved in this CSTL Form 4 and what is his role?
The insider is Juvenal Tobin W, who serves as Chief Commercial Officer of Castle Biosciences Inc (CSTL). He reported a sale of 1,301 common shares and now directly owns 77,694 shares, according to the Form 4 data.